Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Once-daily therapy: less is more.

G Moyle1

  • 1HIV Research Department, Chelsea and Westminster Hospital, London, UK. gm@moyleg.demon.co.uk

International Journal of STD & AIDS
|November 18, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impacts of dance on cognition, psychological symptoms and quality of life in Parkinson's disease.

NeuroRehabilitation·2019
Same author

Amprenavir : A Viewpoint by Graeme Moyle.

Drugs·2016
Same author

Low levels of neurocognitive impairment detected in screening HIV-infected men who have sex with men: The MSM Neurocog Study.

International journal of STD & AIDS·2016
Same author

A cross-sectional study to evaluate the association of hyperbilirubinaemia on markers of cardiovascular disease, neurocognitive function, bone mineral density and renal markers in HIV-1 infected subjects on protease inhibitors.

HIV clinical trials·2016
Same author

Screening for chronic comorbid diseases in people with HIV: the need for a strategic approach.

HIV medicine·2012
Same author

Longer prior exposure to zidovudine/lamivudine-containing combination antiretroviral therapy, age, and male gender are each associated with reduced subcutaneous adipose tissue.

HIV clinical trials·2012

People with HIV prefer once-daily antiretroviral therapy (ART). Many ART options are available as once-daily pills, with more expected soon.

Area of Science:

  • Medical science
  • Pharmacology
  • HIV/AIDS research

Background:

  • A significant trend towards less frequent medication dosing has emerged in medicine over the past two decades.
  • Patient surveys reveal a strong preference among individuals with HIV for once-daily dosing regimens and compact therapeutic options.

Purpose of the Study:

  • To review the current landscape and future potential of once-daily antiretroviral therapy (ART) for HIV management.
  • To highlight the growing availability and patient-driven demand for simplified HIV treatment regimens.

Main Methods:

  • Literature review of available antiretroviral medications.
  • Analysis of patient preference surveys regarding dosing frequency.
  • Projection of future treatment options based on current drug development.

Related Experiment Videos

Main Results:

  • Four key antiretrovirals, including tenofovir, didanosine, lamivudine, and efavirenz, are currently available as once-daily therapies.
  • The selection of once-daily HIV treatment options is expanding rapidly.

Conclusions:

  • The increasing availability of once-daily ART aligns with patient preferences for convenience and adherence.
  • The pipeline suggests that two distinct lines of once-daily HIV therapy may be accessible within the next 12-18 months, further simplifying treatment.